Insider Transactions in Q2 2024 at Nurix Therapeutics, Inc. (NRIX)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 20
2024
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,000
-29.27%
|
$400,000
$20.01 P/Share
|
|
Jun 13
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,864
-8.59%
|
$31,688
$17.02 P/Share
|
|
Jun 13
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,864
+7.91%
|
$1,864
$1.86 P/Share
|
|
Jun 12
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,900
-8.74%
|
$32,300
$17.01 P/Share
|
|
Jun 12
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+8.04%
|
$1,900
$1.86 P/Share
|
|
Jun 05
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
400
-1.98%
|
$6,800
$17.0 P/Share
|
|
Jun 05
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+1.94%
|
$400
$1.86 P/Share
|
|
Jun 03
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,596
-7.45%
|
$27,132
$17.01 P/Share
|
|
Jun 03
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,596
+6.93%
|
$1,596
$1.86 P/Share
|
|
May 02
2024
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,499
-4.87%
|
$41,988
$12.83 P/Share
|
|
Apr 30
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,513
-7.09%
|
$18,156
$12.04 P/Share
|
|
Apr 30
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,924
+8.8%
|
-
|
|
Apr 30
2024
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,007
-4.82%
|
$24,084
$12.04 P/Share
|
|
Apr 30
2024
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,206
+6.04%
|
-
|
|
Apr 30
2024
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,387
-1.89%
|
$16,644
$12.04 P/Share
|
|
Apr 30
2024
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,886
+3.28%
|
-
|